Investigating how the CARM1-NFIB axis affects small cell lung cancer
Official title: Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-10879050 · Data updated 2026-11-12
This study is looking at how a specific pathway in small cell lung cancer affects tumor growth, and it hopes to find new treatment options by testing a potential drug that targets this pathway for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $618,833 |
| NIH project number | 5R01CA272843-02 |
| Project ID | NIH-10879050 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with small cell lung cancer who have limited treatment options.
✕Less likely to help
Patients with other types of lung cancer or those who are not diagnosed with small cell lung cancer may not benefit from this research.
What this research studies
This research focuses on understanding the role of the CARM1-NFIB signaling pathway in small cell lung cancer (SCLC). Researchers have identified that CARM1, an arginine methyltransferase, modifies NFIB, a transcription factor that promotes tumor growth and metastasis in SCLC. By using genetically engineered mouse models, the study aims to explore the mechanisms behind this interaction and evaluate the potential of small molecule inhibitors targeting CARM1 as a new treatment option for SCLC patients.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for small cell lung cancer, improving treatment options for patients.
How similar studies have gone: Other research has shown promise in targeting similar molecular pathways in cancer, suggesting potential for success in this approach.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Mazur, Pawel K. — University of Tx Md Anderson Can Ctr
- Study coordinator: Mazur, Pawel K.
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.